Persistent activation of Signal Transducer and Activator of Transcription (STAT)3 occurs in a high percentage of tumors, including colorectal cancer (CRC), thereby contributing to malignant cell proliferation and survival. Although STAT3 is recognized as an attractive therapeutic target in CRC, conventional approaches aimed at inhibiting its functions have met with several limitations. Moreover, the factors that sustain hyper-activation of STAT3 in CRC are not yet fully understood. The identification of tumor-specific STAT3 cofactors may facilitate the development of compounds that interfere exclusively with STAT3 activity in cancer cells. Here, we show that progranulin, a STAT3 cofactor, is upregulated in human CRC as compared to nontumor tissue/cells and its expression correlates with STAT3 activation. Progranulin physically interacts with STAT3 in CRC cells, and its knockdown with a specific antisense oligonucleotide (ASO) inhibits STAT3 activation and restrains the expression of STAT3-related oncogenic proteins, thus causing cell cycle arrest and apoptosis. Moreover, progranulin knockdown reduces STAT3 phosphorylation and cell proliferation induced by tumor-infiltrating leukocyte (TIL)-derived supernatants in CRC cell lines and human CRC explants. These findings indicate that CRC exhibits overexpression of progranulin, and suggest a role for this protein in amplifying the STAT3 pathway in CRC.

Laudisi, F., Cherubini, F., Di Grazia, A., Dinallo, V., Di Fusco, D., Franze, E., et al. (2019). Progranulin sustains STAT3 hyper-activation and oncogenic function in colorectal cancer cells. MOLECULAR ONCOLOGY, 13(10), 2142-2159 [10.1002/1878-0261.12552].

Progranulin sustains STAT3 hyper-activation and oncogenic function in colorectal cancer cells

Cherubini F.
Membro del Collaboration Group
;
Dinallo V.
Membro del Collaboration Group
;
Ortenzi A.
Membro del Collaboration Group
;
Monteleone I.
Membro del Collaboration Group
;
Monteleone G.
Supervision
;
Stolfi C.
2019-01-01

Abstract

Persistent activation of Signal Transducer and Activator of Transcription (STAT)3 occurs in a high percentage of tumors, including colorectal cancer (CRC), thereby contributing to malignant cell proliferation and survival. Although STAT3 is recognized as an attractive therapeutic target in CRC, conventional approaches aimed at inhibiting its functions have met with several limitations. Moreover, the factors that sustain hyper-activation of STAT3 in CRC are not yet fully understood. The identification of tumor-specific STAT3 cofactors may facilitate the development of compounds that interfere exclusively with STAT3 activity in cancer cells. Here, we show that progranulin, a STAT3 cofactor, is upregulated in human CRC as compared to nontumor tissue/cells and its expression correlates with STAT3 activation. Progranulin physically interacts with STAT3 in CRC cells, and its knockdown with a specific antisense oligonucleotide (ASO) inhibits STAT3 activation and restrains the expression of STAT3-related oncogenic proteins, thus causing cell cycle arrest and apoptosis. Moreover, progranulin knockdown reduces STAT3 phosphorylation and cell proliferation induced by tumor-infiltrating leukocyte (TIL)-derived supernatants in CRC cell lines and human CRC explants. These findings indicate that CRC exhibits overexpression of progranulin, and suggest a role for this protein in amplifying the STAT3 pathway in CRC.
2019
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/12 - GASTROENTEROLOGIA
Settore BIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICA
English
Con Impact Factor ISI
JAK-STAT; SHP-2; anti-apoptotic proteins; antisense oligonucleotide; cyclin D1; tumor-infiltrating leukocytes
Laudisi, F., Cherubini, F., Di Grazia, A., Dinallo, V., Di Fusco, D., Franze, E., et al. (2019). Progranulin sustains STAT3 hyper-activation and oncogenic function in colorectal cancer cells. MOLECULAR ONCOLOGY, 13(10), 2142-2159 [10.1002/1878-0261.12552].
Laudisi, F; Cherubini, F; Di Grazia, A; Dinallo, V; Di Fusco, D; Franze, E; Ortenzi, A; Salvatori, I; Scaricamazza, S; Monteleone, I; Sakamoto, N; Mon...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
2019 - Mol Oncol.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 10.26 MB
Formato Adobe PDF
10.26 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/224998
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 16
social impact